CLAIMS

1. A composition comprising a carrier and, *(I)* a PDE4 inhibitor and *(II)* an anti-cholinergic agent selected from the group consisting of tiotropium, and pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof, in an effective therapeutic amount to treat inflammatory disease or obstructive airways disease.

2. The composition according to claim 1 wherein said obstructive airways disease is asthma, COPD, or other obstructive airways disease exacerbated by bronchial hyper-reactivity or bronchospasm.

3. The composition according to claim 1 wherein said PDE4 inhibitor is a compound of Formula (1.1.1):



(1.1.1)

wherein:

-R^1 is –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_2-C_4) alkenyl; phenyl; –$N(CH_3)_2$; (C_3-C_6) cycloalkyl; (C_3-C_6) cycloalkyl–(C_1-C_3) alkyl; or (C_1-C_6) alkylcarbonyl; where said alkyl, phenyl or alkenyl group is substituted by 0 to 2 of –OH, (C_1-C_3) alkyl, or –CF_3, or 0 to 3 of halo;

-R^2 and R^3 are each independently selected from the group consisting of –H; (C_1-C_{14}) alkyl; (C_1-C_7) alkoxy–(C_1-C_7) alkyl; (C_2-C_{14}) alkenyl; (C_3-C_7) cycloalkyl; (C_3-C_7) cycloalkyl–(C_1-C_2) alkyl; a saturated or unsaturated (C_4-C_7) heterocyclic–$(CH_2)_n$ group where n is 0, 1 or 2, containing as the heteroatom one or two of the group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR^4 where R^4 is –H or (C_1-C_4) alkyl; and a group of partial Formula (1.1.2):



(1.1.2)

—where —

--a is an integer from 1 to 5;

--b and c are 0 or 1;

--R^5 is –H; –OH; (C_1-C_5) alkyl; (C_2-C_5) alkenyl; (C_1-C_5) alkoxy; (C_3-C_6) cycloalkoxy; halo; $–CF_3$; $–CO_2R^6$; $–CONR^6R^7$; $–NR^6R^7$; $–NO_2$; or $–SO_2NR^6R^7$ where R^6 and R^7 are each independently –H; or (C_1-C_4) alkyl;

--Z is –O–; –S–; $–SO_2–$; –C(=O)–; or $–N(R^8)–$ where R^8 is –H; or (C_1-C_4) alkyl; and

--Y is (C_1-C_5) alkylene; or (C_2-C_6) alkenylene; substituted by 0 to 2 of (C_1-C_7) alkyl or (C_3-C_7) cycloalkyl; wherein each of said above-recited alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups is substituted 0 to 14, preferably 0 to 5, of (C_1-C_2) alkyl, CF_3, or halo; and

-R^9 and R^{10} are each independently selected from the group consisting of –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_6-C_{10}) aryl; and (C_6-C_{10}) aryloxy;

or a pharmaceutically acceptable salt thereof.

4. The composition according to claim 3 wherein the PDE4 inhibitor comprises a member selected from the group consisting of:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

5. The composition according to claim 3 wherein the PDE4 inhibitor is 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine.

6. The composition according to claim 1 wherein the anti-cholinergic agent comprises a member selected from the group consisting of tiotropium, and pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof, and a compound of Formula (2.1.1):



(2.1.1)

wherein X^- is a physiologically acceptable anion.

7. The composition according to claim 6 wherein said physiologically acceptable anion, X^-, is selected from the group consisting of fluoride, F^-; chloride, Cl^-; bromide, Br^-; iodide, I^-; methanesulfonate, $CH_3S(=O)_2O^-$; ethanesulfonate, $CH_3CH_2S(=O)_2O^-$; methylsulfate, $CH_3OS(=O)_2O^-$; benzene sulfonate, $C_6H_5S(=O)_2O^-$; *p*-toluenesulfonate, and 4-CH_3-$C_6H_5S(=O)_2O^-$.

8. The composition according to claim 7 wherein the physiologically acceptable anion, X^-, is bromide, Br^-.

9. The composition according to claim 6 wherein the anti-cholinergic agent comprises a 3-α compound.

10. The composition according to claim 9 wherein the anti-cholinergic agent is selected from the group consisting of tiotropium bromide and (1α, 2β, 4β, 5α, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa--9-azoniatricyclo[3.3.1.$0^{2,4}$]nonane bromide, represented by Formula (2.1.2) or Formula (2.1.3):



(2.1.2)



(2.1.3)

11. A method for the treatment of obstructive airways or inflammatory disease, comprising administering to a mammal *(I)* a PDE4 inhibitor and, *(II)* an anti-cholinergic agent comprising a member selected from the group consisting of tiotropium and a pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof, in a therapeutically effective amount to treat the disease when administered by inhalation.

12. The method according to claim 11 wherein the obstructive airways disease is asthma, COPD, or other obstructive airways disease exacerbated by bronchial hyper-reactivity or bronchospasm.

13. The method of treatment according to claim 12 wherein the mammal is a human being.

14. The method according to claim 11 wherein the administration comprises simultaneous or sequential delivery of the PDE4 inhibitor and anti-cholinergic agent in the form of an aerosol or dry powder.

15. The method according to claim 11 wherein the PDE4 inhibitor comprises a compound of Formula (1.1.1):



(1.1.1)

wherein:

-R^1 is –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_2-C_4) alkenyl; phenyl; –$N(CH_3)_2$; (C_3-C_6) cycloalkyl; (C_3-C_6) cycloalkyl–(C_1-C_3) alkyl; or (C_1-C_6) alkylcarbonyl; where said alkyl, phenyl or alkenyl group is substituted by 0 to 2 of –OH, (C_1-C_3) alkyl, or –CF_3, or 0 to 3 of halo;

-R^2 and R^3 are each independently selected from the group consisting of –H; (C_1-C_{14}) alkyl; (C_1-C_7) alkoxy–(C_1-C_7) alkyl; (C_2-C_{14}) alkenyl; (C_3-C_7) cycloalkyl; (C_3-C_7) cycloalkyl–(C_1-C_2) alkyl; a saturated or unsaturated (C_4-C_7) heterocyclic–$(CH_2)_n$ group where n is 0, 1 or 2, containing as the heteroatom one or two of the

group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR^4 where R^4 is –H or $(C_1$-$C_4)$ alkyl; and a group of partial Formula (1.1.2):



(1.1.2)

—where —

--a is an integer from 1 to 5;

--b and c are 0 or 1;

--R^5 is –H; –OH; $(C_1$-$C_5)$ alkyl; $(C_2$-$C_5)$ alkenyl; $(C_1$-$C_5)$ alkoxy; $(C_3$-$C_6)$ cycloalkoxy; halo; $–CF_3$; $–CO_2R^6$; $–CONR^6R^7$; $–NR^6R^7$; $–NO_2$; or $–SO_2NR^6R^7$ where R^6 and R^7 are each independently –H; or $(C_1$-$C_4)$ alkyl;

--Z is –O–; –S–; $–SO_2–$; –C(=O)–; or $–N(R^8)–$ where R^8 is –H; or $(C_1$-$C_4)$ alkyl; and

--Y is $(C_1$-$C_5)$ alkylene; or $(C_2$-$C_6)$ alkenylene; substituted by 0 to 2 of $(C_1$-$C_7)$ alkyl or $(C_3$-$C_7)$ cycloalkyl; wherein each of said above-recited alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups is substituted 0 to 14, preferably 0 to 5, of $(C_1$-$C_2)$ alkyl, CF_3, or halo; and

-R^9 and R^{10} are each independently selected from the group consisting of –H; $(C_1$-$C_6)$ alkyl; $(C_1$-$C_6)$ alkoxy; $(C_6$-$C_{10})$ aryl; and $(C_6$-$C_{10})$ aryloxy;

or a pharmaceutically acceptable salt thereof.

16. The method according to claim 15 wherein the PDE4 inhibitor comprises a member selected from the group consisting of:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

17. The method according to claim 11 wherein the anti-cholinergic agent comprises a member selected from the group consisting of tiotropium, and pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof, and a compound of Formula (2.1.1):



(2.1.1)

wherein X^- is a physiologically acceptable anion.

18. The method according to claim 17 wherein the physiologically acceptable anion, X^-, is bromide, Br^-.

19. A method of treatment according to claim 18 wherein the anti-cholinergic agent comprises a group consisting of tiotropium bromide and (1α, 2β, 4β, 5α, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa--9-azoniatricyclo[3.3.1.$0^{2,4}$]nonane bromide, represented by Formula (2.1.2) or Formula (2.1.3):



(2.1.2)



(2.1.3)

20. The composition according to claim 1 comprising a carrier, (I) a PDE4 inhibitor and, (II) an anticholinergic agent, in a form suitable for administration by inhalation.

21. The composition according to claim 20 wherein the form suitable for administration by inhalation comprises simultaneous or sequential delivery of components (I) and (II) in the form of an aerosol or dry powder.

22. The composition according to claim 20 wherein the PDE4 inhibitor comprises a compound of formula (1.1.1)



(1.1.1)

wherein:

-R^1 is –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_2-C_4) alkenyl; phenyl; –$N(CH_3)_2$; (C_3-C_6) cycloalkyl; (C_3-C_6) cycloalkyl–(C_1-C_3) alkyl; or (C_1-C_6) alkylcarbonyl; where said alkyl, phenyl or alkenyl group is substituted by 0 to 2 of –OH, (C_1-C_3) alkyl, or –CF_3, or 0 to 3 of halo;

-R^2 and R^3 are each independently selected from the group consisting of –H; (C_1-C_{14}) alkyl; (C_1-C_7) alkoxy–(C_1-C_7) alkyl; (C_2-C_{14}) alkenyl; (C_3-C_7) cycloalkyl; (C_3-C_7) cycloalkyl–(C_1-C_2) alkyl; a saturated or unsaturated (C_4-C_7) heterocyclic–$(CH_2)_n$ group where n is 0, 1 or 2, containing as the heteroatom one or two of the group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR^4 where R^4 is –H or (C_1-C_4) alkyl; and a group of partial Formula (1.1.2):



(1.1.2)

—where —

--a is an integer from 1 to 5;

--b and c are 0 or 1;

--R^5 is –H; –OH; (C_1-C_5) alkyl; (C_2-C_5) alkenyl; (C_1-C_5) alkoxy; (C_3-C_6) cycloalkoxy; halo; –CF_3; –CO_2R^6; –$CONR^6R^7$; –NR^6R^7; –NO_2; or –$SO_2NR^6R^7$ where R^6 and R^7 are each independently –H; or (C_1-C_4) alkyl;

--Z is –O–; –S–; –SO_2–; –C(=O)–; or –$N(R^8)$– where R^8 is –H; or (C_1-C_4) alkyl; and

--Y is (C_1-C_5) alkylene; or (C_2-C_6) alkenylene; substituted by 0 to 2 of (C_1-C_7) alkyl or (C_3-C_7) cycloalkyl; wherein each of said above-recited alkyl,

alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups is substituted 0 to 14, preferably 0 to 5, of (C_1-C_2) alkyl, CF_3, or halo; and

-R^9 and R^{10} are each independently selected from the group consisting of –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_6-C_{10}) aryl; and (C_6-C_{10}) aryloxy;

or a pharmaceutically acceptable salt thereof.

23. The composition according to claim 22 wherein the PDE4 inhibitor comprises a compound selected from the group consisting of

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

24. The composition according to claim 20 wherein the anticholinergic agent comprises a compound of Formula (2.1.1)



(2.1.1)

wherein X^- is a physiologically acceptable anion.

25. The composition according to claim 24 wherein said physiologically acceptable anion, X^-, is selected from the group consisting of fluoride, F^-;

chloride, Cl^-; bromide, Br^-; iodide, I^-; methanesulfonate, $CH_3S(=O)_2O^-$; ethanesulfonate, $CH_3CH_2S(=O)_2O^-$; methylsulfate, $CH_3OS(=O)_2O^-$; benzene sulfonate, $C_6H_5S(=O)_2O^-$; *p*-toluenesulfonate, and 4-CH_3-$C_6H_5S(=O)_2O^-$.

26. The composition according to claim 25 wherein said physiologically acceptable anion, X^-, is bromide, Br^-.

27. The composition according to claim 24 wherein the anticholinergic agent comprises a 3-α compound.

28. The composition according to claim 27 wherein the anticholinergic agent is selected from the group consisting of tiotropium bromide and (1α, 2β, 4β, 5α, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa--9-azoniatricyclo[3.3.1.$0^{2,4}$]non-ane bromide, represented by Formula (2.1.2):



(2.1.2)

29. A package containing the composition according to claim 20 capable of insertion into a device for simultaneous or sequential delivery of the composition in the form of an aerosol or dry powder.

30. The package according to claim 29 wherein the composition comprises a PDE4 inhibitor selected from the group consisting of:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

31. The package according to claim 29 wherein the composition comprises an anticholinergic agent of Formula (2.1.1)



(2.1.1)

wherein X^- is a physiologically acceptable anion.

32. The package according to claim 31 wherein the physiologically acceptable anion, X^-, is bromide, Br^-.

33. The package according to claim 29 wherein the composition comprises an anticholinergic agent selected the group consisting of tiotropium bromide and (1α, 2β, 4β, 5α, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa--9-azoniatricyclo[3.3.1.$0^{2,4}$]non-ane bromide, represented by Formula (2.1.2):



(2.1.2)

34. The package according to claim 29 wherein said device is a metered dose inhaler or a dry powder inhaler.